On April 4, 2024 Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, reported that it will present a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (AACR) (Free AACR Whitepaper) 2024 being held on April 5-10, 2024 (Press release, Egle Therapeutics, APR 4, 2024, View Source [SID1234641804]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the poster, entitled "EGL-001 is a novel immunocytokine designed to specifically target and disarm T regulatory cells in the tumor microenvironment".

Egle scientists present evidence that EGL-001, a CTLA-4 targeted IL-2 dominant negative mutein, selectively binds to T regulatory (Treg) cells and inhibits Treg IL-2 signaling.

The resulting reduction of Treg frequencies and functionality, as observed in ex vivo human tumor cultures and in vivo mouse models, promotes effector T cell responses. Accordingly, EGL-001 induces anti-tumor responses in combination with anti-PD-1 treatment in mouse models.

EGL-001 is the first drug candidate to emerge from Egle’s discovery platform, and it’s being developed for treatment of advanced solid tumors and to restore responsiveness to PD-1 inhibition.

Session Category: Immunology; Session Title: Immune Modulation with Cytokines; Session Date and Time: Tuesday Apr 9, 2024 9:00 AM – 12:30 PM; Location: Poster Section 4; Poster Board Number: 23 Published Abstract Number: 4079

On April 4, 2024 Adcendo ApS ("Adcendo"), a biotech company focused on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, reported that it will be presenting novel data on the expression of its novel ADC target uPARAP and the in vitro and in vivo activity of a uPARAP targeting ADC in glioblastoma multiforme (GBM) at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, held in San Diego, California, from April 5th to April 10th, 2024 (Press release, ADCendo, APR 4, 2024, View Source [SID1234641771]). The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

uPARAP is a novel ADC target overexpressed by mesenchymal cancer cells including soft tissue and bone sarcomas, GIST as well as mesothelioma and glioblastoma, and has the potential to play a key role in modulating the tumor microenvironment.

The data demonstrate that uPARAP is strongly over-expressed in glioblastoma cells and that a uPARAP targeting ADC exhibits strong in vivo anti-tumor activity in a glioblastoma PDX model. Based on its differentiated expression profile and rapid internalization capabilities, uPARAP is an attractive novel target for the development of a uPARAP-targeting ADC in this hard-to-treat disease area with a high unmet medical need due to limited treatment options.

Details of the poster presented presentation are as follow:

Presentation title: 6355/16 – Urokinase plasminogen activator receptor-associated protein (uPARAP) is overexpressed in human glioblastomas and is a novel attractive target for antibody-drug conjugates (ADC)

Track: Clinical Research/Immunology

Session: Antibodies 2

Authors: I. Gregersen1, C. R. Løkke1, J. B. Lange1, P. Barkholt1, C. Côme1, T. Broberg1, O. D. Lærum2, M. M. Petersen1, M. Knuuttila3, S.-M. Käkönen3, C. M. Lynch1, D. Mumberg1, N. Behrendt2, L. H. Engelholm 1,2

Date & Time: April 9th, 1.30pm – 5.00pm PDT

Abstracts are available in an online itinerary planner found here, and will be available in an online only supplement to the AACR (Free AACR Whitepaper) journal Cancer Research one month after the conference.

Dominik Mumberg, Chief Scientific Officer at Adcendo, said: "We are excited to share promising data on the expression of uPARAP in glioblastoma as well as encouraging in vivo activity of a uPARAP targeting ADC. In addition to its highly differentiated expression profile in multiple mesenchymal cancers, uPARAP is a constitutively recycling endocytic receptor with unique internalization properties, making it a very attractive ADC target for the benefit of patients."Lars Engelholm, Associate Professor, and group leader at the Cancer Invasion Section of the Finsen Laboratory, said: "Treatment progress and therapeutic options in glioblastoma have so far been very limited. We are extremely encouraged by the data highlighted in this study, which provides further evidence on the potential effectiveness of uPARAP as a novel target for ADCs in glioblastoma multiforme. We look forward to continuing our scientific collaboration with Adcendo to further deepen our insights into the biology of uPARAP and its utility as target for ADC development in multiple mesenchymal cancers."

On April 4, 2024 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, reported that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum (Press release, Revolution Medicines, APR 4, 2024, View Source [SID1234641787]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s participation are as follows:

23rd Annual Needham Healthcare Conference
Conference Dates: April 8-11, 2024
Fireside Chat Time/Date: 1:30 – 2:10 p.m. ET on Thursday, April 11, 2024
Location: Virtual; webcast available
Stifel Targeted Oncology Forum
Conference Dates: April 16-17, 2024
Fireside Chat Time/Date: 3:30 – 3:55 p.m. ET on Tuesday, April 16, 2024
Location: Virtual; webcast available

To access the live webcasts of the Needham and Stifel fireside chats, please visit the "Events & Presentations" page of Revolution Medicines’ website at View Source Additionally, a replay of each webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the conference.

On April 4, 2024 NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, reported that it will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas. The conference will be held in San Diego, April 5-10, 2024 (Press release, NanoString Technologies, APR 4, 2024, View Source [SID1234641805]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NanoString and its customers will showcase 110 posters and highlight its products in three oral presentations focusing on unique biological insights generated with its platforms. The abstracts that will be featured include 14 studies exploring spatial biology using the CosMx Spatial Molecular Imager (SMI), 46 studies powered by GeoMx Digital Spatial Profiler (DSP), and 59 studies exploring gene expression using the nCounter Analysis System.

"NanoString customers are using the highest plex protein and RNA spatial biology panels commercially available on cancer patient samples, making fundamental discoveries and answering key questions about patient response to advanced cancer therapies utilized today. These research contributions are changing our understanding of the underlying biology driving tumor growth and metastases, greatly accelerating the development of new therapeutic approaches," said Joseph Beechem, Ph.D., Chief Scientific Officer and Senior Vice President of Research and Development, NanoString Technologies. "The spatial biology revolution has arrived! These new biological insights will help the field evolve from treating cancer to curing cancer."

Nanostring Product Showcase in Theater B, April 9, 10:00-11:00 AM PT

Dr. Beechem will present NanoString’s spatial biology roadmap and highlight recent advancements in a talk entitled "Highest-Plex Spatial Multi-Omics – Eliminating the Blind Spots in Your Research." He will be joined by Arutha Kulasinghe, Ph. D. Senior Research Fellow and Leader of the Clinical-oMx Lab at the University of Queensland, who will speak on "Uncoupling pathways involved in immunotherapy resistance: insights from deep tissue profiling."
Oral presentations:

Sunday, April 7, 4:20-4:35 PM PT – Golnaz Morad, Ph. D., from MD Anderson Cancer Center will present, "Digital spatial profiling of metastatic brain tumors reveals association of the tumor microbiome with immune alterations in the tumor microenvironment." This study investigated the role of distinct microbial communities in metastatic brain tumors through metagenomic sequencing of stool and saliva samples, 16S rRNA gene sequencing of tumor samples and spatial transcriptome and proteome analysis using NanoString platforms. The spatially resolved NanoString work was able to unequivocally resolve intracellular versus extracellular bacterial signals, greatly expanding our understanding of the innate-immune mediated anti-bacterial response within the tumor microenvironment.
Monday, April 8, 4:05-4:20 PM PT – Jingyi Cao, Ph. D from Gene Lay Institute of Immunology and Inflammation, Brigham and Women’s Hospital and Harvard Medical School will present, "Therapy-associated remodeling of pancreatic cancer revealed by single-cell spatial transcriptomics and optimal transport analysis." This study utilizes high-plex single-cell spatial molecular imaging (NanoString’s CosMx 1K Cell Characterization Panel) to dissect treatment-remodeled multicellular neighborhoods and malignant-stroma cell interactions in primary resected human pancreatic cancer. It revealed IL-6 family signaling as a potential inducer of chemoresistance.
Tuesday, April 9, 3:50-4:05 PM PT – Isobelle Wall, Kings College London, will present, "Spatial transcriptomics delineates tumor heterogeneity in NACT triple-negative breast cancer." This study utilizes spatial transcriptomics to investigate the histological and molecular heterogeneity of triple-negative breast cancer pre- and post-neoadjuvant chemotherapy. It revealed potential chemo-resistant properties and spatially distinct immune cell compositions associated with treatment response.
NanoString team members will welcome customers at booth 331.

On April 4, 2024 Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, reported that it will be presenting a poster, demonstrating its new findings on the discovery of novel macrocyclic peptide radioligands for tumor therapy by mRNA display in collaboration with research partner, UCB, a global pharmaceutical company, at this year’s American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, held 5-10 April 2024 in San Diego, California (Press release, Ariceum Therapeutics, APR 4, 2024, View Source [SID1234641772]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB’s mRNA-display technology platform, ExtremeDiversity. Macrocyclic peptides are potent ligands for radioligand therapeutics (RLT) that aim to selectively deliver radioisotopes to cancer tissues to eradicate tumor cells while limiting the damage to surrounding tissues. This new data highlights the potential of UCB’s mRNA display platform for fast and efficient discovery of highly specific macrocyclic peptides with optimal binding properties suitable for RLT.

Manfred Rüdiger, Chief Executive Officer at Ariceum Therapeutics, said: "Following our exclusive, strategic research collaboration with UCB, we look forward to presenting new findings related to the identification of highly specific macrocyclic peptides for use in radioligand therapeutics at this year’s AACR (Free AACR Whitepaper) Annual Meeting. These data have positive implications for the future development of RLT and are a potential game-changer in precision cancer therapy. AACR (Free AACR Whitepaper)’s Annual Meeting is the perfect industry forum at the forefront of cancer research at which to present our findings."

Details of the poster presentation are as follow:

Title: Discovery of novel macrocyclic peptide radioligands for tumor therapy by mRNA display
Presenting Author: Anika Jaekel, Senior Director, Head of Translational Biology and Non-Clinical Pharmacology at Ariceum Therapeutics
Session Category: Experimental and Molecular Therapeutics
Session Title: Radiation, Theranostics, Radiotheranostics, Normal Tissue, and Cellular Stress
Session Date and Time: Tuesday 9 April 2024, 1:30 PM – 5:00 PM PDT
Location: Poster Section 29
Poster Board Number: 7
Abstract Number: 6025

Abstracts are available in an online itinerary planner here and will be available in on online only supplement to the AACR (Free AACR Whitepaper) journal Cancer Research one month after the conference.